Seeking Alpha

Baxter International (BAX) slips 2.2% premarket after Phase III testing on its Alzheimer's drug...

Baxter International (BAX) slips 2.2% premarket after Phase III testing on its Alzheimer's drug immunoglobulin (IG) - always a long shot - failed to meet its co-primary endpoints. (PR)
Comments (1)
  • fish4uinmd
    , contributor
    Comments (188) | Send Message
     
    Baxter is a great company which I have owned for over 20 years. This is but a bump in the road for them...I am proud to be a shareholder of a company that has helped countless people have a better quality of life.
    7 May 2013, 09:05 AM Reply Like
DJIA (DIA) S&P 500 (SPY)
ETF Tools
Find the right ETFs for your portfolio:
Seeking Alpha's new ETF Hub
ETF Investment Guide:
Table of Contents | One Page Summary
Read about different ETF Asset Classes:
ETF Selector

Next headline on your portfolio:

|